ReviewCurrent drug discovery technologies2025
Biological Activity and Therapeutic Potential of Coumarin Derivatives: A Comprehensive Review.
Review in Current drug discovery technologies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Artificial intelligence-driven discovery of coumarin-based therapeutics: Revolutionizing target identification and validation.Pharmaceutical science advances · 2026Review
- Synthesis of Spiro-Bridged 3,4-Dihydrocoumarins Through an Organocatalytic Cascade Sequence Diels-Alder/Nucleophilic Ring Closing.Molecules (Basel, Switzerland) · 2026Article
- Coumarin hybrids as privileged therapeutic scaffolds: biological activities, mechanistic insights, and therapeutic potential.RSC advances · 2026Review
- Coumarin-based small molecules for diabetes management: rational design, computational studies, synthesis, and biological evaluation.Journal of computer-aided molecular design · 2026Article
- Integrated widely targeted UPLC-MS/MS metabolomics and transcriptomics reveal MYB-linked variation in bioactive phenolics across five kiwifruit varieties.Food chemistry. Molecular sciences · 2026Article
- Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Imperatorin: A Furanocoumarin with Potential in Combating Cancer Development and Progression-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advances in Coumarin Fluorescent Probes for Medical Diagnostics: A Review of Recent Developments.Biosensors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coumarins, naturally occurring benzopyrones, have garnered significant attention due to their diverse pharmacological activities and therapeutic potential. Derived from natural sources and synthetic routes such as the Perkin and Pechmann reactions, these compounds exhibit a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, antidiabetic, and neuroprotective effects. The structure-activity relationship of coumarins highlights the critical role of substitutions at specific positions on the benzopyrone ring, enhancing their efficacy and selectivity. Notable applications include anticancer activities, with coumarin derivatives inhibiting tumor growth and inducing apoptosis in breast cancer and melanoma cells, and neuroprotection, particularly in Alzheimer's and Parkinson's diseases, through acetylcholinesterase inhibition and β- amyloid modulation. Additionally, coumarins show promise in combating drug-resistant pathogens and oxidative stress. Despite their potential, challenges such as toxicity and bioavailability remain. Future research should focus on optimizing coumarin scaffolds and advancing clinical evaluations to establish their role as next-generation therapeutic agents.
Indexed as
Identifiers
40207758What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.